Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech filing packed with immuno-neurology science, milestone payment clauses, and clinical-trial risk language can feel overwhelming. Alector’s disclosures are particularly dense because they intertwine cutting-edge TREM2 research, the Alector Brain Carrier platform, and multi-million-dollar collaboration terms. If you have ever searched for Alector SEC filings explained simply, you already know the challenge.
Stock Titan solves it. Our AI reads every Alector quarterly earnings report 10-Q filing, Alector annual report 10-K simplified, and Alector 8-K material events explained in real time, highlighting cash-runway updates, R&D spend trends, and partnership revenue without the jargon. Interactive summaries let you drill from a one-paragraph view down to page-level citations, so understanding Alector SEC documents with AI becomes straightforward instead of time-consuming.
Need to track insider confidence? Get instant alerts for Alector insider trading Form 4 transactions and monitor Alector Form 4 insider transactions real-time. Planning a compensation analysis? The latest Alector proxy statement executive compensation is parsed to surface salary, bonus, and option grants. For momentum traders, our dashboards pair Alector executive stock transactions Form 4 with trial-timeline 8-K disclosures, giving context that raw prices alone miss.
Whether you want fast Alector earnings report filing analysis before the call, or you’re comparing quarter-over-quarter burn rates, our platform keeps every filing type—from S-3 shelves to definitive proxies—one click away. Save hours, surface what matters, and make better decisions with AI-powered summaries, expert annotations, and EDGAR-speed updates.
Alector, Inc. Schedule 13G/A summary: This amendment reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals (Peter Kolchinsky and Rajeev Shah) each beneficially own 0 shares of Alector common stock, representing 0.0% of the class as of the reporting date. The filing lists the reporting persons' principal business address at c/o RA Capital Management, 200 Berkeley Street, Boston, MA, and states the entities are Delaware partnerships while the individuals are U.S. citizens. The reporting persons expressly disclaim status as a group and confirm the securities were not acquired to influence control of the issuer. The filing incorporates a Joint Filing Agreement by reference.
Alector, Inc. (ALEC) submitted a Form 144 reporting a proposed sale of 76,446 common shares with an aggregate market value of $152,892.00, against 101,212,329 shares outstanding. The filing states the shares were acquired as restricted stock on 03/01/2023 and lists an approximate sale date of 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The notice also discloses a prior sale of 16,488 shares on 06/02/2025 for gross proceeds of $22,065.89. The signer represents there is no undisclosed material adverse information and includes standard Rule 144 attestations.
Insider transaction: On 06/20/2025, Alector, Inc. (ALEC) director Kristine Yaffe sold 1,000 shares of common stock at a price of $1.44 per share, according to a Form 4 filed with the SEC.
Following the sale, Yaffe’s direct beneficial ownership stands at 95,409 shares. No derivative security activity was reported, and the filing was signed on 06/23/2025 by attorney-in-fact Danielle Pasqualone.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
